Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hcw Biologics Inc (NQ: HCWB )

0.5340 +0.0340 (+6.80%)
Streaming Delayed Price Updated: 2:25 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hcw Biologics Inc

< Previous 1 2 3 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
HCWB Stock Earnings: HCW Biologics Reported Results for Q2 2024
HCW Biologics just reported results for the second quarter of 2024. 
Via InvestorPlace
HCWB Stock Earnings: HCW Biologics Reported Results for Q1 2024
HCW Biologics just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Looking Into HCW Biologics's Return On Capital Employed
Via Benzinga
HCWB Stock Earnings: HCW Biologics Misses EPS, Misses Revenue for Q4 2023
HCWB stock results show that HCW Biologics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Why Anavex Life Sciences Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Anavex Life Sciences Corp. (NASDAQ: AVXL) moved lower during Monday’s session after the company reported fourth-quarter financial results. 
Via Benzinga
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
From HCW Biologics, Inc
Via GlobeNewswire
Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
HCW9218 is the lead product candidate of HCW Biologics Inc. 
From HCW Biologics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Company will provide an update for clinical development and intellectual property programs, Including recent achievements and expected milestones in the next 12 months 
From HCW Biologics, Inc
Via GlobeNewswire
Nerdy And 3 Other Stocks Under $4 Insiders Are Aggressively Buying
The Dow Jones closed higher by around 90 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
$3M Bet On This Technology Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
$25M Bet On This Consumer Cyclical Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by over 250 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Recap: HCW Biologics Q1 Earnings
HCW Biologics (NASDAQ:HCWB) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:15 AM. Here's what investors need to know about the announcement. Earnings HCW Biologics reported in-line EPS... 
Via Benzinga
HCW Biologics: Q1 Earnings Insights
HCW Biologics (NASDAQ:HCWB) reported its Q1 earnings results on Tuesday, May 9, 2023 at 07:15 AM. Here's what investors need to know about the announcement. Earnings HCW Biologics reported in-line EPS... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
HCW Biologics Secures $26.25 Million Non-Dilutive Financing With Asset-Backed Development Loan
From HCW Biologics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer 
From HCW Biologics, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Smith Micro Software And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
US crude oil futures traded lower this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
CASI Pharmaceuticals And 2 Other Stocks Under $4 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 1,000 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
Why Citi Trends Is Trading Lower By 17%, Here Are 47 Stocks Moving In Wednesday's Mid-Day Session
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 77% to $2.35. Bright Minds priced overnight marketed offering of 2.858 million units at $1.40 per unit. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.